2,845 Shares in AstraZeneca PLC $AZN Purchased by Finemark National Bank & Trust

Finemark National Bank & Trust acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) in the third quarter, HoldingsChannel.com reports. The fund acquired 2,845 shares of the company’s stock, valued at approximately $218,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. NewSquare Capital LLC lifted its holdings in shares of AstraZeneca by 149.3% in the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after buying an additional 218 shares during the period. Rakuten Investment Management Inc. acquired a new position in AstraZeneca during the third quarter worth $31,000. FSA Wealth Management LLC grew its holdings in AstraZeneca by 376.0% during the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock worth $33,000 after acquiring an additional 376 shares during the period. VSM Wealth Advisory LLC purchased a new position in AstraZeneca in the second quarter worth $33,000. Finally, E Fund Management Hong Kong Co. Ltd. lifted its holdings in AstraZeneca by 144.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company’s stock valued at $36,000 after acquiring an additional 275 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of several research analyst reports. TD Cowen restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Citigroup started coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and set a $103.00 price objective on shares of AstraZeneca in a report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $204.01 on Tuesday. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The company’s 50-day moving average price is $138.16 and its 200 day moving average price is $103.25. AstraZeneca PLC has a 52 week low of $122.48 and a 52 week high of $212.71. The stock has a market cap of $316.40 billion, a price-to-earnings ratio of 67.78, a PEG ratio of 1.59 and a beta of 0.34.

AstraZeneca Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. This represents a dividend yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. AstraZeneca’s dividend payout ratio (DPR) is 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.